Kinnevik invests USD 30 million in Cityblock to support nationwide expansion
Kinnevik AB (publ) ("Kinnevik”) today announced its participation with USD 30m in Cityblock’s recent USD 192m funding round. Cityblock will use the newly raised capital to accelerate deployment of its community and value-based care model nationwide, bringing desperately needed transformation to the most vulnerable and underserved communities across the US.
In just four years since its launch, Cityblock has achieved positive results with its comprehensive care model. Data from Cityblock’s first member cohort show a 15 percent reduction in emergency room visits and a 20 percent reduction in in-patient hospital stays. Cityblock sees around 70 percent member engagement compared to the health plan average of 5-7 percent and receives average NPS scores of over 85, compared to the provider average of 15. While delivering these outcomes, Cityblock is experiencing 3x year-over-year revenue growth.
Georgi Ganev, CEO of Kinnevik commented: “Cityblock addresses a massive need in the US supporting the most vulnerable population groups with a community-based, scalable care model. This is a great example how value-based care can transform the healthcare experience and achieve sustainable change, even for populations which are fundamentally disadvantaged in today’s healthcare system. We are proud to continue to support the founders Toyin Ajayi and Iyah Romm by investing well above pro-rata as they expand the model across the US.”
The USD 192m funding round was an extension of Cityblock’s Series C round. Tiger Global led this latest round, with participation from other existing investors alongside Kinnevik, including Maverick Ventures, General Catalyst, and Wellington Management. The Series C extension brings Cityblock’s total fundraising since its founding in 2017 to about USD 500m.
In Kinnevik’s Year-End Release 2020, Kinnevik’s investment in Cityblock was valued at SEK 841m. Cityblock has continued its strong operational performance during the first months of 2021, and the recent funding round provides strong reference points for the valuation of Cityblock relative to listed comparable businesses. In combination, these factors underpin a value of Kinnevik’s investment that corresponds to a value uplift of SEK 1.0bn or SEK 3.6 per Kinnevik share, excluding the USD 30m in new capital invested in the funding round at hand.
The reassessed fair value of Kinnevik’s investment in Cityblock will be finalized and reported in Kinnevik’s Interim Report for the first quarter, to be published on 22 April 2021.
For further information, visit www.kinnevik.com or contact:
Torun Litzén, Director Investor Relations
Phone +46 (0)70 762 00 50
Kinnevik is an industry focused investment company with an entrepreneurial spirit. Our purpose is to make people’s lives better by providing more and better choice. In partnership with talented founders and management teams we build challenger businesses that use disruptive technology to address material, everyday consumer needs. As active owners, we believe in delivering both shareholder and social value by building long-term sustainable businesses that contribute positively to society. We invest in Europe, with a focus on the Nordics, the US, and selectively in other markets. Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families. Kinnevik’s shares are listed on Nasdaq Stockholm’s list for large cap companies under the ticker codes KINV A and KINV B.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
REC Silicon - Notice of Annual General Meeting20.4.2021 15:12:01 CEST | Press release
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Lysaker, Norway - April 20, 2021: Notice is hereby given that the Annual General Meeting of REC Silicon ASA (REC) will be held at the offices of Schjødt, Ruseløkkveien 14, Oslo, Norway on May 11, 2021 at 4.00 pm CET. Please find attached Notice of the General Meeting and the Recommendation of the Nomination Committee. All documents are available at https://www.recsilicon.com/investors/agm/ Due to the extraordinary situation with Covid-19, and in light of prevailing travel and meeting recommendations and restrictions, the Board urges shareholders to vote through submission of proxy forms prior to the meeting and not attend the meeting in person. For further information, please contact: James A. May II, Chief Financial Officer Phone: +1 509 989 1023 Email: email@example.com Nils O. Kjerstad, IR Contact Phone: +47 9135 6659 Email: firstname.lastname@example.org About REC
Årsredovisning 2020 är nu publicerad20.4.2021 15:00:00 CEST | Pressemelding
2021-04-20 PRESSRELEASE Årsredovisning 2020är nu publicerad Arcoma publicerar idag sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.arcoma.se/about-us/investors. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Adviser är Erik Penser Bank (tel: 08-4638300, e-mail: email@example.com) För mer information om bolaget besök www.arcoma.se För ytterligare information, vänligen kontakta: Arcomas VD Sanna Rydbe
Skyharbour’s Partner Company Valor Completes Airborne Survey at Hook Lake Uranium Project, Saskatchewan20.4.2021 14:00:00 CEST | Press release
VANCOUVER, British Columbia, April 20, 2021 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQB: SYHBF) (Frankfurt: SC1P) (the “Company”) is pleased to announce that partner company Valor Resources Limited (“Valor”) entered into a contract with Precision GeoSurveys Inc. through TerraLogic Exploration Inc. (“TerraLogic”), the Company’s geological consultants, to undertake a detailed airborne survey over the Hook Lake Project (previously North Falcon Point). The survey commenced in early April 2021 and is now complete. TerraLogic designed the low-level airborne magnetic and VLF-EM survey to cover the entire Hook Lake claim area, using a fixed-wing aircraft, at 75m line-spacing totaling 5,100 line-km. Final data processing, data interpretation, target selection and recommendations for follow-up ground-based exploration and drilling programs will also be handled by TerraLogic. This process is expected to take approximately six weeks, followed immediately by the recommended fi
Acarix publicerar årsredovisningen för 202020.4.2021 13:00:00 CEST | Pressemelding
Pressmeddelande Malmö, 20 april 2021 Acarix publicerar årsredovisningen för 2020 Idag, tisdagen den 20 april, publicerar Acarix sin årsredovisning för verksamhetsåret 2020 på bolagets hemsida www.acarix.com. Årsredovisningen finns även bifogad i pressreleasen. För mer information, vänligen kontakta: Per Persson, vd, e-mail: firstname.lastname@example.org, telefon: +46 73 600 59 90 Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande vid den tidpunkt som anges av företagets nyhetsdistributör, GlobeNewswire. Om Acarix Acarix grundades 2009 och är noterat på Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix CADScor®System använder en avancerad sensor som placeras på huden ovanför hjärtat för att lyssna på ljudet av hjärtkontraktion och turbulent flöde. Det har utformats för att vara ett allt-i-ett-system i den meningen att signalen från hjärtat spelas in, bearbetas och visas som en patientspecifik s k CAD-score på skärmen. Presentation av mätresul
Acarix publishes the annual report for 202020.4.2021 13:00:00 CEST | Press release
Press release Malmö, Sweden, April 20, 2021 Acarix publishes the annual report for 2020 Today, Tuesday April 20, Acarix is publishing its Annual Report for 2020 on the company website www.acarix.com. The Annual Report is also attached to this press release. For further information, please contact: Per Persson, CEO, E-mail: email@example.com, Phone: +46 73 600 59 90 The information was provided, through the agency of the above contact person, for publication at the time specified by the company's news distributor, GlobeNewswire. About Acarix: Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the devi
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex20.4.2021 12:30:00 CEST | Press release
– Tuberous sclerosis complex (TSC) represents a third indication for GW’s cannabidiol in Europe – – TSC causes epilepsy in up to 85% of patients, and up to 60% of those patients do not respond to standard anti-epileptic medicines1,2,3– LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Commission (EC) has approved the Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older. This approval, which represents the third indication for GW’s cannabidiol in Europe, paves the way for the expanded launch of the medicine across Europe. “This is an exciting moment for patients, and their families, who are affected by this debilitating disease and may benefit from this treatment. This approval is
Fingerprint Cards AB: invitation to the first quarter 2021 results presentation20.4.2021 11:30:00 CEST | Press release
Fingerprint Cards AB (Fingerprints™) will host a telephone conference and webcast presentation of its first quarter 2021 results, on April21, 2021 at 09:00 CEST. Fingerprints’ CEO Christian Fredrikson will present the report together with CFO Per Sundqvist in a combined webcast and telephone conference. The presentation will be held in English. Time: Wednesday, April 21, 2021 at 09:00 am CEST. Location: combined webcast and telephone conference. The report is available at https://www.fingerprints.com/ The webcast and the presentation material can be accessed through https://edge.media-server.com/mmc/p/5dpwm66j where it is also possible to ask questions. For media and analysts: The telephone conference dial-in is +44 (0) 2071 928000 (international participants) or 08-506 921 80 (Swedish participants). Please state conference ID 9862978. About Fingerprints Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and se